70 million dollars for MedTech robotics Vitestro

The Dutch medtech company Vitestro has completed an oversubscribed Series B financing round of 70 million US dollars. The company intends to use the capital to further develop its robotic platform for automated blood collection and prepare for market readiness.

In particular, the financing is intended to advance the next generation of the Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™) system. At the same time, the company is planning to expand clinical studies, prepare for regulatory approvals and scale up its technology internationally.

Robotics, AI and imaging for automated blood collection

Vitestro, based in Utrecht, is developing a system that can perform fully automated diagnostic blood sampling. The system combines robotics, multimodal imaging and artificial intelligence to identify suitable veins, place the needle precisely and take blood samples with high accuracy.

The aim is to make one of the world's most common medical procedures more efficient, standardized and patient-friendly. Billions of diagnostic blood samples are taken every year around the world - often under great time pressure and with high staffing levels.

Broad investor consortium participates

The new financing round is supported by a broad consortium of strategic investors and institutional investors. The new investors include leading organizations from the healthcare sector, while existing investors have further expanded their support.

The investors involved include:

• Labcorp Venture Fund
• Mayo Clinic
• Sutter Health
• InterVest
• MGFO
• PGGM
• Puma Venture Capital
• ROM Utrecht
• Invest-NL
• EIC Fund
• Fred Moll
• NYBC Ventures
• Sonder Capital

Solution for staff shortages in the healthcare sector

According to CEO and co-founder Toon Overbeeke, the oversubscribed financing round shows the investors' confidence in the company's vision. The technology has developed from an innovative idea to a clinically validated solution. The aim now is to integrate it more broadly into everyday clinical practice.

In particular, the autonomous platform is intended to take over routine blood sampling and thus relieve the burden on medical staff. At the same time, standardized procedures, greater precision and more predictable processes could improve quality and efficiency in diagnostic centers.

Preparing for FDA approval and international expansion

Part of the funding will be used to prepare for the US approval process via the FDA de novo pathway. In parallel, Vitestro is working on scaling up production, further clinical studies and the establishment of an international sales structure.

The company is also receiving support from robotics pioneer Fred Moll, who is co-founder of Intuitive Surgical and Auris Health, among others. In his opinion, Vitestro is addressing one of the largest and so far hardly modernized clinical processes.

The company intends to use the new capital to accelerate the development of its platform, launch further pilot programs with hospitals and gradually roll out its technology worldwide. The aim is to establish automated blood collection as an integral part of modern diagnostic workflows in the future.